Health

Zika Virus Infection Drug Market Huge Growth by Valneva SE, Moderna, Inc, Novavax, Inc, Johnson & Johnson Services, Inc, Themis Bioscience GmbH

Global Zika Virus Infection Drug Market

Global Zika virus infection Drug Market By Strains Type (Aedes Aegypti, Aedes Albopictus), Treatment Type (Preventive Treatment, Symptomatic Treatment and Others), Drugs (Chloroquine, Daptomycin and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Trends and Forecast to 2026

Global Zika Virus Infection Drug Market is rise gradually to a steady CAGR in the forecast period of 2019-2026. The advancement in serological testing and introduction of Nucleic Acid Amplification Testing (NAT) to identify Zika virus in order to avail the treatment faster is the key factor for market growth.

Get Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-zika-virus-infection-drug-market

Some of the major competitors currently working in the global Zika virus infection drug market are   Emergent BioSolutions Inc, Valneva SE, Moderna, Inc, Novavax, Inc, Johnson & Johnson Services, Inc, Themis Bioscience GmbH, Sanofi, IMV Inc, Takeda Pharmaceutical Company Limited, Carogen Corporation, GeoVax, Tychan Pte. Ltd, WuXi Biologics, Inovio Pharmaceuticals, Inc and few among others.

Market Definition: 

Zika virus infection is also known as Zika fever is characterized by mosquito-borne viral disease which is spread by a bite of an infected Aedes species mosquito. It is estimated one in every five people does not have any symptoms at beginning. The first outbreaks in human being were identified in 1952 in the Uganda and Tanzania.

According to the statistics published in U.S. Department of Health & Human Services, it was estimated 666 Zika virus disease cases were found in the United States in the year of 2017. It is more prevalent in male population. The market growth is increased by introduction of novel therapies and rise in government initiatives may increase the Zika virus infection drug market.

Market Drivers

  • Increase in advancement of serological testing for Zika virus infection is driving the market
  • Demand of novel therapies for treating Zika virus infections is also acting as a driver for the market
  • Increase in special designation from the regulatory authorities is boosting the growth of the market
  • Rising awareness about treatment and technological advancement is driving the growth of market

Market Restraints

  • Effective treatment is either unavailable due to less prevalence of Zika infection is restricting the growth for the market
  • Lack of awareness about clinical development and novel therapies for Zika infection treatment will hamper the market growth
  • Less financial support for research and development in many low-income countries

Inquiry Before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-zika-virus-infection-drug-market

Segmentation: Global Zika virus infection Drug Market

By Strains Type

  • Aedes Aegypti
  • Aedes Albopictus

By Treatment Type

  • Preventive Treatment
  • Symptomatic Treatment
  • Others

By Drugs

  • Chloroquine
  • Daptomycin
  • Others

By Route of Administration

  • Oral
  • Injectable

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Key Developments in the Market:

In August 2019, Moderna, Inc received Fast Tract designation from the FDA for Zika vaccine (mRNA-1893) for the preventive treatment of Zika virus infection in healthy adult. This vaccine is currently in phase I clinical trial study evaluating clinical safety and efficacy in healthy subject. This fast track approval accelerates the review timeline and enhances the guidance and support with the FDA, which can bring novel vaccine for patients suffering from Zika virus infections to get regulatory approval faster.

In November 2018, Emergent BioSolutions Inc in collaboration with Valneva SE reported positive interim results for the phase I clinical trial study of VLA1601, a vaccine candidate against the Zika virus infections. This collaboration will greatly enhances the development efforts and bring a unique benefits to the vulnerable populations.

Competitive Analysis:

Global Zika virus infection drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global Zika virus infection drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Get Full TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-zika-virus-infection-drug-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:                       

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

Tags

Related Articles

Close